{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:13:46Z","timestamp":1791112426161,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.amjcard.2007.10.023","type":"journal-article","created":{"date-parts":[[2007,12,26]],"date-time":"2007-12-26T16:24:29Z","timestamp":1198686269000},"page":"625-630","source":"Crossref","is-referenced-by-count":146,"title":["Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia\u2020\u2020A list of study investigators appears in the Appendix."],"prefix":"10.1016","volume":"101","author":[{"given":"John F.","family":"Paolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yale B.","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Kher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2007.10.023_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.10.023_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.10.023_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2007.10.023_bib4","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2007.10.023_bib5","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2007.10.023_bib6","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.10.023_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1994.00420140051007","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2007.10.023_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2007.10.023_bib9","article-title":"Dosage and titration patterns of extended release niacin in clinical practice","volume":"113","author":"Kamal-Bahl","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.10.023_bib10","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2007.10.023_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.amjcard.2007.10.023_bib12","series-title":"Physicians\u2019 Desk Reference","first-page":"1730","article-title":"Product label for Niaspan\u00ae (Kos Pharmaceuticals, Inc., Miami, Florida)","year":"2007"},{"key":"10.1016\/j.amjcard.2007.10.023_bib13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Development and validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2007.10.023_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus","volume":"264","author":"Garg","year":"1990","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907021327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907021327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T07:06:22Z","timestamp":1557126382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914907021327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0002914907021327"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2007.10.023","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}